Linezolid

From IDWiki
(Redirected from Zyvoxam)

Background

  • Oxazolidinone antibiotic

Mechanism of Action

  • Inhibits the 50S ribosome of Gram-positive bacteria

Spectrum of Activity

Dosing

  • Linezolid 600 mg PO/IV q12h

Renal Dosing

  • No adjustment needed

Safety

Adverse Drug Reactions

  • Serotonin syndrome when taken concurrently with certain psychiatric medications
    • Ideally hold SSRIs when starting linezolid
  • Cytopenias, including thrombocytopenia (most common), anemia, and leukopenia (least common)
    • More common with prolonged use, e.g. after 2 weeks
    • Likely more common with higher dose (600 mg versus 300 mg)

Long-Term Use

  • The generally-recommended maximum therapy is 28 days
  • However, linezolid is used in the treatment for MDR-TB in much longer courses
  • The most common adverse effects were peripheral neuropathy (64%), myelosuppression (22%), optic neuritis (5%), GI effects (2%), and rash (2%)1
  • About 15% of patients had to permanently discontinue due to adverse effects
  • Risk of adverse reactions increases with time2
    • <10% at 2 weeks (for higher, standard dose)
    • 12% at 4 weeks
    • 20% at 8 weeks
    • 40% at 16 weeks
    • 55% at 32 weeks

Drug-Drug Interactions

  • Coadminitration with rifampin decreases AUC and peak by 32 and 21%, respectively
  • Increases warfarin INR
  • Weak, reversible, nonselective MAO inhibitor, leading to a risk of serotonin syndrome if coadministered with other MAOIs (and may SSRIs)

References

  1. ^  Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei, Linda Barkane, Andrea Benedetti, Sarah K Brode, James C M Brust, Jonathon R Campbell, Vicky Wai Lai Chang, Dennis Falzon, Lorenzo Guglielmetti, Petros Isaakidis, Russell R Kempker, Maia Kipiani, Liga Kuksa, Christoph Lange, Rafael Laniado-Laborín, Payam Nahid, Denise Rodrigues, Rupak Singla, Zarir F Udwadia, Dick Menzies, N Ahmad, P Baghaei, L Barkane, A Benedetti, SK Brode, JCM Brust, JR Campbell, VWL Chang, D Falzon, L Guglielmetti, P Isaakidis, RR Kempker, M Kipiani, L Kuksa, Z Lan, C Lange, R Laniado-Laborín, P Nahid, D Rodrigues, R Singla, ZF Udwadia, D Menzies. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet Respiratory Medicine. 2020;8(4):383-394. doi:10.1016/s2213-2600(20)30047-3.
  2. ^  G. B. Migliori, B. Eker, M. D. Richardson, G. Sotgiu, J-P. Zellweger, A. Skrahina, J. Ortmann, E. Girardi, H. Hoffmann, G. Besozzi, N. Bevilacqua, D. Kirsten, R. Centis, C. Lange. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal. 2009;34(2):387-393. doi:10.1183/09031936.00009509.